SUCCESSFUL TREATMENT OF SOMNAMBULISM WITH OROS-METHYLPHENIDATE

被引：0
|
作者：
Nigam, M. [1 ,2 ]
Zadra, A. [1 ,3 ]
Boucetta, S. [1 ]
Gibbs, S. A. [1 ,2 ,4 ]
Warby, S. [1 ,5 ]
Montplaisir, J. [1 ,5 ]
Desautels, A. [1 ,2 ,4 ]
机构：
[1] Hop Sacre Coeur Montreal, Ctr Adv Res Sleep Med, Montreal, PQ, Canada
[2] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada
[3] Univ Montreal, Dept Psychol, Montreal, PQ, Canada
[4] Hop Sacre Coeur Montreal, Neurol Serv, Montreal, PQ, Canada
[5] Univ Montreal, Dept Psychiat, Montreal, PQ, Canada
来源：
SLEEP MEDICINE | 2019年 / 64卷
基金：
加拿大健康研究院;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S279 / S280
页数：2
相关论文
共 50 条
  • [21] Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD
    Lee, Sung Hee
    Kim, So Won
    Lee, Min Goo
    Yook, Ki-Hwan
    Greenhill, Laurence L.
    Frandin, Kelly N.
    Hong, Hyun Ju
    PSYCHIATRY RESEARCH, 2011, 186 (2-3) : 338 - 344
  • [22] Optimizing methylphenidate delivery to improve treatment for ADHD:: Results with OROS® (methylphenidate HCl)
    Lerner, MA
    Modi, NB
    Gupta, S
    PEDIATRIC RESEARCH, 2000, 47 (04) : 29A - 29A
  • [23] OROS® formulation of methylphenidate in treatment for ADHD:: Duration of effect
    Wigal, SB
    PEDIATRIC RESEARCH, 2002, 51 (04) : 21A - 21A
  • [24] Norepinephrine transporter-3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment
    Cho, Soo-Churl
    Kim, Bung-Nyun
    Cummins, Tarrant D. R.
    Kim, Jae-Won
    Bellgrove, Mark A.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (03) : 380 - 389
  • [25] Effects of OROS methylphenidate (OROS MPH) treatment in children and adolescents with ADHD, mental retardation and epilepsy
    Kesic, A.
    Lakic, A.
    Dronjak, D.
    Stupar, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S420 - S421
  • [26] The incidence of personality disorder in adults with ADHD, and the effects on response to treatment with OROS methylphenidate (OROS MPH)
    Casciol, Carissa
    Sassoon, Rachel E.
    Carroll-Sharpe, Abigail
    Essick, Gregory K.
    Baranek, Grace T.
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 245S - 245S
  • [27] Methylphenidate (OROS® formulation) -: A viewpoint
    Swanson, JM
    Lerner, M
    Steinhoff, K
    Wigal, S
    CNS DRUGS, 2001, 15 (06) : 502 - 503
  • [28] Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate
    Buitelaar, Jan K.
    Kooij, J. J. Sandra
    Antoni Ramos-Quiroga, J.
    Dejonckheere, Joachim
    Casas, Miguel
    van Oene, Joop C.
    Schauble, Barbara
    Trott, Goetz-Erik
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (02): : 554 - 560
  • [29] SUCCESSFUL TREATMENT OF NIGHT TERRORS AND SOMNAMBULISM WITH PAROXETINE
    LILLYWHITE, AR
    WILSON, SJ
    NUTT, DJ
    BRITISH JOURNAL OF PSYCHIATRY, 1994, 164 : 551 - 554
  • [30] OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: A randomized, placebo-controlled cross-over study
    Bron, Tannetje I.
    Bijlenga, Denise
    Boonstra, A. Marije
    Breuk, Minda
    Pardoen, Willem F. H.
    Beekman, Aartjan T. F.
    Kooij, J. J. Sandra
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 (04) : 519 - 528
12345